Zymeworks Inc (ZYME)
NASDAQ:ZYME
Want to see ZYME full AI Analyst Report?
Lenvatinib, Tislelizumab, Zanidatamab, Temozolomide, Pamiparib, Ociperlimab, Fruquintinib, Bat1706, Lbl-007, Bgb-A445, Sitravatinib, Bgb-15025, Surzebiclimab
Advanced Malignancies
Phase III
Active Not Recruiting
Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies
Nov 14, 2019
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Zymeworks Inc (ZYME) have in its pipeline
ZYME is currently developing the following drugs: Lenvatinib, Tislelizumab, Zanidatamab, Temozolomide, Pamiparib, Ociperlimab, Fruquintinib, Bat1706, Lbl-007, Bgb-A445, Sitravatinib, Bgb-15025, Surzebiclimab. These drug candidates are in various stages of clinical development as the company works toward FDA approval.